FindTrial
Sign In

Effect of Propranolol In patients with Cavernous malformations of the central nervous system: a randomised controlled trial

Effect of Propranolol In patients with Cavernous malformations of the central nervous system: a randomised controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020707
Enrollment
Unknown
Registered
2019-01-14
Start date
2019-01-01
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cavernous malformations of the central nervous system

Interventions

Experimental group:Oral propranolol for 4 to 8 weeks before surgery
Control group:Without invention before surgery

Sponsors

Xuanwu Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with symptomatic cavernous malformations of the central nervous system requiring surgical treatment; 2. Written informed consent to participate in the study prior to any study procedures; 3. Negative pregnancy test at time of enrollment for women of child-bearing potential; 4. Heart rate greater than 50 beats per minute; 5. Systolic blood pressure > 90 mmHg.

Exclusion criteria

Exclusion criteria: 1. Patients with any contraindication for propranolol; 2. Unstable diabetes; 3. Severe asthma; 4. History of cardiac dysfunction; 5. Heart rate less than 50 beats per minute; 6. Systolic blood pressure = 90 mmHg; 7. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Lesion Size on MRI;Neurological outcome;—

Secondary

MeasureTime frame
Biomarkers of the blood and tissue samples;—

Countries

China

Contacts

Public ContactZhang Hongqi

Xuanwu Hospital, Capital Medical University

renjian1129@126.com+86 13601374152

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026